Biomea Fusion Inc BMEA 深 沪

Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib

Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data for icovamenib in type 2 diabetes, highlighting durable efficacy and a favorable safety profile.

03-14 23:51

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

2025-06-23 11:00

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Biomea Fusion reports significant weight loss in obese monkeys with BMF-650, an oral GLP-1 RA. 12-15% weight reduction observed, better than leading candidate. IND filing planned for H2 2025, with Phase I to start late 2025.

2025-06-18 11:00

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion, Inc. has launched a public offering of its common stock and warrants, with underwriters having an option to purchase up to an additional 15% of the shares. The offering, subject to market conditions, is expected to close on June 20, 2025, with Jefferies acting as sole book running manager.

2025-06-17 20:33

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

Biomea Fusion announced positive results from the Phase I COVALENT-103 trial of BMF-500 in relapsed or refractory acute leukemia patients, especially those with FLT3 mutations. The data showed significant bone marrow responses, complete remission in some patients, and improved survival compared to historicalcontrols. BMF-500 demonstrated good tolerability and no dose-limiting toxicities, supporting its potential as a promising treatment for this high-risk patient population.

2025-06-13 10:45

Rodman & Renshaw Upgrades Biomea Fusion to Buy, Announces $18 Price Target

Rodman & Renshaw analyst Tony Butler upgrades Biomea Fusion (NASDAQ:BMEA) from Neutral to Buy and announces $18 price target.

2024-09-27 04:07

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Theriva Biologics (AMEX:TOVX) shares moved upwards by 34.2% to $6.31 during Monday's pre-market session. The market value of their outstanding shares is at $6.3 million. Emergent BioSolutions (NYSE:EBS) shares rose 17.62% to $10.48. The market value of their outstanding shares is at $549.1 m...

2024-09-02 20:05

Capital One Initiates Coverage On Biomea Fusion with Overweight Rating, Announces Price Target of $25

Capital One analyst Naureen Quibria initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Overweight rating and announces Price Target of $25.

2024-08-30 00:29

Citigroup Maintains Buy on Biomea Fusion, Lowers Price Target to $22

Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers the price target from $45 to $22.

2024-08-27 22:36